家族性地中海热患者秋水仙碱抵抗/不耐受的改良Delphi共识定义
该改良Delphi共识由11名国际成人和儿童风湿病学专家参与,基于系统文献综述形成的问卷,经匿名分析和圆桌会议名义组技术,达成8条核心声明,用于定义家族性地中海热(FMF)患者的秋水仙碱抵抗/不耐受。抵抗定义为3个月内平均每月≥1次临床发作或发作间期持续实验室炎症,并强调评估治疗依从性及疾病活动和不耐受对生活质量的影响。
要点
- 秋水仙碱抵抗定义为3个月内平均每月≥1次发作或发作间期持续实验室炎症。
- 共识强调需评估患者治疗依从性以明确抵抗/不耐受。
- 活动性疾病和秋水仙碱不耐受对生活质量的影响被列为核心声明。
核心结论
- 基于专家意见达成8条循证核心声明,定义FMF患者的秋水仙碱抵抗/不耐受,以指导临床医生和卫生当局。
研究设计与样本
- 采用改良Delphi共识方法,由11名具有FMF专长的国际成人和儿童风湿病学专家组成专家组,基于系统文献综述形成的问卷进行匿名分析,并通过圆桌会议名义组技术讨论定稿。
主要发现
- 专家组就8条定义秋水仙碱抵抗/不耐受的核心声明达成共识。
- 抵抗的定义包括反复临床发作(3个月内平均每月1次或以上发作)或发作间期持续实验室炎症。
- 其他核心声明认可评估治疗依从性的重要性,以及活动性疾病和秋水仙碱不耐受对生活质量的影响。
关键数值与推荐
- 秋水仙碱抵抗:3个月内平均每月≥1次临床发作,或发作间期持续实验室炎症。
- 共识共包含8条核心声明,涉及抵抗定义、依从性评估及生活质量影响。
临床怎么用
- 临床医生可依据该共识声明识别FMF患者的秋水仙碱抵抗/不耐受,并评估治疗依从性及生活质量影响。
- 卫生当局可参考该定义规范FMF管理中秋水仙碱抵抗/不耐受的判定。
局限性
- 共识基于专家意见,而非直接来自前瞻性验证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Colchicine is the main treatment for FMF. Although a number of individuals with FMF are intolerant/resistant to colchicine, there is no standard definition of colchicine resistance/intolerance. We developed a set of evidence-based core statements defining colchicine resistance/intolerance in patients with FMF that may serve as a guide for clinicians and health authorities. METHODS: A set of statements was identified using a modified-Delphi consensus-based approach. The process involved development of an initial colchicine resistance/intolerance-related questionnaire derived from a systematic literature review. The questionnaire, which was completed by an international panel of 11 adult and paediatric rheumatologists with expertise in FMF, was analysed anonymously. The results informed draft consensus statements that were discussed by a round-table expert panel, using a nominal group technique to agree on the selection and wording of the final statements. RESULTS: Consensus among the panel was achieved on eight core statements defining colchicine resistance/intolerance in patients with FMF. A definition of resistance was agreed upon that included recurrent clinical attacks (average one or more attacks per month over a 3-month period) or persistent laboratory inflammation in between attacks. Other core statements recognize the importance of assessing treatment adherence, and the impact of active disease and intolerance to colchicine on quality of life. CONCLUSION: Based on expert opinion, a set of evidence-based core statements defining colchicine resistance/intolerance in patients with FMF were identified to help guide clinicians and health authorities in the management of patients with FMF.
引用
- Özen S, Sag E, Ben-Chetrit E, et al. Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology (Oxford). 2021. PMID: 33331943. doi:10.1093/rheumatology/keaa863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。